论文部分内容阅读
目的观察分析环磷腺苷葡胺辅助治疗慢性心律失常的临床疗效及安全性。方法选取昭平县人民医院2014年4月—2015年3月收治的慢性心律失常患者96例,按照随机数字表法将其均分为环磷腺苷葡胺治疗组(试验组)和常规治疗组(对照组),每组48例。试验组在常规治疗基础上静脉滴注环磷腺苷葡胺,对照组仅采用常规治疗。比较两组患者的临床治疗效果、平均心率及不良反应发生情况。结果试验组治疗有效率为91.7%(44/48),高于对照组的50.0%(24/48),差异有统计学意义(P<0.05)。两组治疗后平均心率高于治疗前,差异有统计学意义(P<0.05),且治疗后试验组平均心率为(57.4±6.5)次/min,高于对照组的(50.9±6.9)次/min,差异有统计学意义(P<0.05)。试验组不良反应发生率为8.3%(4/48),低于对照组的31.3%(15/48),差异有统计学意义(P<0.05)。结论环磷腺苷葡胺辅助治疗慢性心律失常的临床疗效显著,能够调节患者心率、减轻患者症状,提高患者的生活质量。
Objective To observe and analyze the clinical efficacy and safety of cyclic adenosine monophosphate (AMPA) in the treatment of chronic cardiac arrhythmia. Methods Ninety-six patients with chronic arrhythmia who were admitted to Zhaoping People’s Hospital from April 2014 to March 2015 were randomly divided into three groups according to the random number table: (Control group), 48 cases in each group. Experimental group on the basis of conventional treatment of intravenous injection of cyclic AMP, the control group only with conventional treatment. The clinical effects, mean heart rate and adverse reactions of the two groups were compared. Results The effective rate of treatment in trial group was 91.7% (44/48), which was higher than that in control group (50.0%, 24/48). The difference was statistically significant (P <0.05). The average heart rate of the two groups after treatment was significantly higher than that before treatment (P <0.05), and the average heart rate of the experimental group after treatment was (57.4 ± 6.5) times / min, higher than that of the control group (50.9 ± 6.9) / min, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was 8.3% (4/48), which was lower than that in the control group (31.3%, 15/48). The difference was statistically significant (P <0.05). Conclusion CAMP is effective in the treatment of chronic cardiac arrhythmia, which can adjust the heart rate, alleviate the symptoms and improve the quality of life of patients.